Home/Pipeline/TAC-302

TAC-302

Diabetic Peripheral Neuropathic Pain

Phase 2Completed

Key Facts

Indication
Diabetic Peripheral Neuropathic Pain
Phase
Phase 2
Status
Completed
Company

About SPARC

SPARC is a specialized research and development arm that emerged from Sun Pharmaceutical Industries, concentrating on innovative drug delivery technologies and new molecular entities. The company has built a pipeline of novel formulations and new chemical entities targeting complex therapeutic areas with high unmet medical needs. Its strategic focus includes developing non-infringing, patent-protected products that offer significant clinical advantages over existing treatments. SPARC's valuation reflects its potential to deliver breakthrough innovations through its research platforms.

View full company profile